OraSure Technologies, Inc. (OSUR)
OSUR Stock Price Chart
Explore OraSure Technologies, Inc. interactive price chart. Choose custom timeframes to analyze OSUR price movements and trends.
OSUR Company Profile
Discover essential business fundamentals and corporate details for OraSure Technologies, Inc. (OSUR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
17 Nov 1986
Employees
501.00
Website
https://www.orasure.comCEO
Carrie Eglinton Manner
Description
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
OSUR Financial Timeline
Browse a chronological timeline of OraSure Technologies, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.27, while revenue estimate is $28.83m.
Earnings released on 6 May 2026
EPS came in at -$0.32 falling short of the estimated -$0.23 by -39.13%, while revenue for the quarter reached $27.93m , beating expectations by +0.75%.
Earnings released on 25 Feb 2026
EPS came in at -$0.19 falling short of the estimated -$0.17 by -11.76%, while revenue for the quarter reached $26.72m , beating expectations by +1.03%.
Earnings released on 5 Nov 2025
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $27.09m , beating expectations by +2.43%.
Earnings released on 5 Aug 2025
EPS came in at -$0.19 falling short of the estimated -$0.15 by -26.67%, while revenue for the quarter reached $31.24k , missing expectations by -8.03%.
Earnings released on 7 May 2025
EPS came in at -$0.18 falling short of the estimated -$0.15 by -20.00%, while revenue for the quarter reached $934.00k , missing expectations by -96.84%.
Earnings released on 25 Feb 2025
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%, while revenue for the quarter reached $37.45m , beating expectations by +1.87%.
Earnings released on 6 Nov 2024
EPS came in at -$0.01 falling short of the estimated -$0.01 by -22.10%, while revenue for the quarter reached $264.00k , missing expectations by -99.28%.
Earnings released on 6 Aug 2024
EPS came in at $0.07 surpassing the estimated $0.04 by +66.67%, while revenue for the quarter reached $54.34m , beating expectations by +4.23%.
Earnings released on 8 May 2024
EPS came in at $0.04 surpassing the estimated -$0.01 by +766.67%, while revenue for the quarter reached $54.13m , beating expectations by +3.90%.
Earnings released on 27 Feb 2024
EPS came in at $0.27 surpassing the estimated $0.09 by +200.00%, while revenue for the quarter reached $75.88m , beating expectations by +2.38%.
Earnings released on 7 Nov 2023
EPS came in at $0.27 surpassing the estimated $0.07 by +285.71%, while revenue for the quarter reached $89.19m , beating expectations by +18.98%.
Earnings released on 3 Aug 2023
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $85.44m , beating expectations by +74.69%.
Earnings released on 10 May 2023
EPS came in at $0.37 surpassing the estimated $0.14 by +164.29%, while revenue for the quarter reached $154.96m , beating expectations by +22.43%.
Earnings released on 14 Feb 2023
EPS came in at $0.21 surpassing the estimated $0.01 by +2.20k%, while revenue for the quarter reached $123.08m , beating expectations by +26.75%.
Earnings released on 8 Nov 2022
EPS came in at $0.07 surpassing the estimated $0.02 by +274.93%, while revenue for the quarter reached $116.46m , beating expectations by +27.00%.
Earnings released on 9 Aug 2022
EPS came in at -$0.26 falling short of the estimated -$0.13 by -100.00%, while revenue for the quarter reached $80.23m , beating expectations by +14.77%.
Earnings released on 10 May 2022
EPS came in at -$0.28 falling short of the estimated -$0.14 by -100.00%, while revenue for the quarter reached $67.71m , beating expectations by +12.46%.
Earnings released on 23 Feb 2022
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%, while revenue for the quarter reached $63.57m , beating expectations by +2.61%.
Earnings released on 3 Nov 2021
EPS came in at -$0.21 falling short of the estimated -$0.05 by -320.00%, while revenue for the quarter reached $53.92m , beating expectations by +15.75%.
Earnings released on 3 Aug 2021
EPS came in at -$0.02 falling short of the estimated -$0.01 by -148.76%, while revenue for the quarter reached $57.61m , meeting expectations.
OSUR Stock Performance
Access detailed OSUR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
